Reports FY23 revenue $2.8M, consensus $2.07M. “We are pleased with the incredible progress we made in 2023 with our late-stage candidates and on-market product, including the U.S. launch of XACIATO, Sildenafil Cream Phase 2b study completion and Ovaprene Phase 3 study commencement, which put us on track for meaningful milestones in 2024 across multiple programs. In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “I had the pleasure of attending in person both the ARPA-H Sprint for Women’s Health announcement event in Boston in February and the White House reception in March in honor of Women’s History Month where President Biden signed an executive order dedicated to advancing women’s health research, and it is encouraging to see further, comprehensive action aimed at increasing investments in women’s health. They bring focus to and financial support for the entire ecosystem working to boldly innovate for women. We look forward to continuing to execute on our mission to accelerate development of and bring to market innovative treatments that women want and need, and to evaluate a wide range of financing opportunities to fund our robust portfolio. Our 2023 achievements demonstrate our commitment to advancing our late-stage candidates – all of which represent a first-in-category opportunity – while seeking to continue to deliver value for all Dare stakeholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
- Daré Bioscience (DARE) Q4 Earnings Cheat Sheet
- Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience to present additional data from Phase 2b RESPOND study